$PMCB News
Last published 4h ago
- 4h agoPMCBTrading halt: PharmaCyte Biotech, Inc. Cm (PMCB), News pendingNasdaq Trading HaltsHalted 2026-11-12 19:50:00.000 ET, resumption quote none, resumption trade none.
- 1d agoPMCBPharmaCyte Biotech, Inc. Announces Reverse Stock SplitBusiness WireLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that the board of directors of the Company approved a 1-for-19 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on March 30, 2026. The Reverse Split wil ...
- 11mo agoFEMYPMCBPharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital DeploymentBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's strategic approach to
- 1y agoPMCBTNFAPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsBusiness WireTNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies PharmaCyte Biotech, Inc. (NASDAQ:PMCB)
- 1y agoPMCBPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had approximately $15.5 million in
- 1y agoPMCBPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of
- 2y agoMYMDPMCBMyMD Pharmaceuticals Secures Strategic InvestmentsBusiness WireUp to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the
- 2y agoMYMDPMCBPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseBusiness WireSecond external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or
- 2y agoFEMYPMCBPharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.Business WireNew investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has
- 2y agoFEMYPMCBFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechGlobeNewswire- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women in the U.S. - -
- 3y agoPMCBPharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box TechnologyBusiness WireCompany prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
- 3y agoPMCBPharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box TechnologyBusiness WireCompany prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
- 3y agoPMCBPharmaCyte Biotech Announces Final Results of Tender OfferBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock,
- 3y agoOBLGPMCBPTPISNPX+1Oblong Appoints Two New Directors to its BoardBusiness WireJonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new
- 3y agoPMCBPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareBusiness WireConcurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer
- 3y agoPMCBPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of
- 4y agoPMCBPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueGlobeNewswireLAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology,
- 4y agoPMCBPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalBusiness WireCompany Appoints Five New Independent Directors to Reconstituted Board PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell e
- 4y agoPMCBPharmaCyte Biotech Rebukes Iroquois' Commencement of Consent SolicitationBusiness Wire- 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders - Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances to Iroquois with History of Value Destruction - P
- 4y agoPMCBIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.PR NewswireReiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, Hand-Picked Appointees Expresses Disappointment in th
- 4y agoPMCBPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has com
- 4y agoPMCBPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has ach
- 4y agoPMCBPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022Business WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary
- 4y agoPMCBIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSPR NewswireNEW YORK, July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or th
- 4y agoPMCBIROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORSPR NewswireNEW YORK, July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownershi
- 4y agoPMCBPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of a
- 4y agoPMCBIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGPR NewswireBelieves Truly Independent Board Required to Increase Accountability Given PharmaCyte's Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to Appease Stockholders Nominates Seven Experienced High
- 4y agoPMCBPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the fo
- 4y agoPMCBPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced tha
- 4y agoPMCBIROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORSPR NewswireBelieves the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Without Addressing the Real Underlying Issues at the Com
- 4y agoPMCBPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the f
- 4y agoPMCBPharmaCyte Biotech to Implement $10-Million Share Repurchase ProgramBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced tha
- 4y agoPMCBPharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant AscitesBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in
- 4y agoPMCBIroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of DirectorsPR NewswireExpresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareho
- 4y agoPMCBPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the management team will be at
- 4y agoPMCBPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material tha
- 4y agoPMCBPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that PharmaCyte has decided to acce
- 4y agoPMCBPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Lö
- 4y agoPMCBPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed
- 4y agoPMCBPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of an additional, more
- 4y agoPMCBPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDABusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on PharmaCyte's activities
- 4y agoPMCBPharmaCyte Biotech to Present at H.C. Wainwright BioConnect ConferenceBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be featured as a prese
- 4y agoPMCBPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the empty capsule material tha
- 4y agoPMCBPharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability StudyBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed
- 4y agoPMCBPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational HighlightsBusiness WirePharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial results for its secon
- 4y agoPMCBPharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing AssayBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more
- 4y agoPMCBPharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical StudyBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study
- 5y agoPMCBPharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin IrritationBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material tha
- 5y agoPMCBPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNABusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test o
- 5y agoPMCBPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility TestsBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food a